{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:21:03Z","timestamp":1774066863757,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40272-022-00551-w","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T18:02:32Z","timestamp":1671386552000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characterization of Cardiac Function by Echocardiographic Global Longitudinal Strain in a Cohort of Children with Neurofibromatosis Type 1 Treated with Selumetinib"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2272-0992","authenticated-orcid":false,"given":"Thomas","family":"Caiffa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antimo","family":"Tessitore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Magnolato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Petz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bobbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Chicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biancamaria","family":"D\u2019Agata Mottolese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egidio","family":"Barbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,18]]},"reference":[{"issue":"4","key":"551_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.clindermatol.2020.03.010","volume":"38","author":"M Jafry","year":"2020","unstructured":"Jafry M, Sidbury R. RASopathies. Clin Dermatol. 2020;38(4):455\u201361.","journal-title":"Clin Dermatol"},{"issue":"26","key":"551_CR2","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550\u201360.","journal-title":"N Engl J Med"},{"issue":"3","key":"551_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10880-018-9584-5","volume":"26","author":"SE Jensen","year":"2019","unstructured":"Jensen SE, Patel ZS, Listernick R, Charrow J, Lai JS. Lifespan development: symptoms experienced by individuals with neurofibromatosis type 1 associated plexiform neurofibromas from childhood into adulthood. J Clin Psychol Med Settings. 2019;26(3):259\u201370.","journal-title":"J Clin Psychol Med Settings"},{"issue":"12","key":"551_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, Singh G, Akshintala S, Baldwin A, Dombi E, Ukwuani S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018;20(12):1643\u201351.","journal-title":"Neuro Oncol"},{"issue":"15","key":"551_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u201342.","journal-title":"N Engl J Med"},{"issue":"4","key":"551_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40272-020-00399-y","volume":"22","author":"F Baldo","year":"2020","unstructured":"Baldo F, Grasso AGG, Cortellazzo Wiel L, Maestro A, Trojniak MP, Murru FM, et al. Selumetinib in the treatment of symptomatic intractable plexiform neurofibromas in neurofibromatosis type 1: a prospective case series with emphasis on side effects. Pediatr Drugs. 2020;22(4):417\u201323.","journal-title":"Pediatr Drugs"},{"key":"551_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pediatrneurol.2019.11.010","volume":"105","author":"J Passos","year":"2020","unstructured":"Passos J, Nzwalo H, Azevedo M, Tavares M, Nunes S. Dramatic improvement of a massive plexiform neurofibroma after administration of selumetinib. Pediatr Neurol. 2020;105:69\u201370.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"551_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","volume":"147","author":"V Esp\u00edrito Santo","year":"2020","unstructured":"Esp\u00edrito Santo V, Passos J, Nzwalo H, Carvalho I, Santos F, Martins C, et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J Neurooncol. 2020;147(2):459\u201363.","journal-title":"J Neurooncol"},{"issue":"1","key":"551_CR9","first-page":"95","volume":"2","author":"S Jackson","year":"2020","unstructured":"Jackson S, Baker EH, Gross AM, Whitcomb P, Baldwin A, Derdak J, et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neurooncol Adv. 2020;2(1):95.","journal-title":"Neurooncol Adv."},{"issue":"1","key":"551_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00281-0","volume":"9","author":"A Harder","year":"2021","unstructured":"Harder A. MEK inhibitors: novel targeted therapies of neurofibromatosis associated benign and malignant lesions. Biomark Res. 2021;9(1):1\u20139.","journal-title":"Biomark Res."},{"issue":"7","key":"551_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, et al. NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol. 2021;39(7):797\u2013806.","journal-title":"J Clin Oncol"},{"issue":"1","key":"551_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","volume":"27","author":"MJ Fisher","year":"2021","unstructured":"Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, et al. Cabozantinib for neurofibromatosis type 1\u2013related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021;27(1):165\u201373.","journal-title":"Nat Med"},{"issue":"12","key":"551_CR13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","volume":"13","author":"KA Robertson","year":"2012","unstructured":"Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012;13(12):1218\u201324.","journal-title":"Lancet Oncol"},{"issue":"2","key":"551_CR14","first-page":"289","volume":"19","author":"RI Jakacki","year":"2017","unstructured":"Jakacki RI, Dombi E, Steinberg SM, Goldman S, Kieran MW, Ullrich NJ, et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017;19(2):289\u201397.","journal-title":"Neuro Oncol"},{"issue":"9","key":"551_CR15","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1212\/WNL.0000000000013296","volume":"98","author":"J Hwang","year":"2022","unstructured":"Hwang J, Mang YH, Lee BH, Hwa KP, Kim KW. Efficacy and safety of selumetinib in pediatric patients with neurofibromatosis type 1: a systematic review and meta-analysis. Neurology. 2022;98(9):e938\u201346.","journal-title":"Neurology"},{"issue":"2","key":"551_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1200\/JGO.2015.000802","volume":"1","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected cardiovascular toxicities in patients with cancer treated with MEK inhibitors: a comparative systematic review and meta-analysis. J Glob Oncol. 2015;1(2):73\u201382.","journal-title":"J Glob Oncol."},{"issue":"1","key":"551_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjci\/jeu184","volume":"16","author":"JU Voigt","year":"2015","unstructured":"Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/industry task force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015;16(1):1\u201311.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"551_CR18","first-page":"253","volume":"18","author":"M Cameli","year":"2017","unstructured":"Cameli M, Mondillo S, Galderisi M, Mandoli GE, Ballo P, Nistri S, et al. Speckle tracking echocardiography: a practical guide. G Ital Cardiol. 2017;18(4):253\u201369.","journal-title":"G Ital Cardiol"},{"issue":"2","key":"551_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jcmg.2017.11.017","volume":"11","author":"E Potter","year":"2018","unstructured":"Potter E, Marwick TH. Assessment of left ventricular function by echocardiography: the case for routinely adding global longitudinal strain to ejection fraction. JACC Cardiovasc Imaging. 2018;11(2):260\u201374.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"25","key":"551_CR20","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25):2751\u201368.","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"551_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506\u201313.","journal-title":"Genet Med"},{"key":"551_CR22","doi-asserted-by":"crossref","unstructured":"Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575\u20138.","DOI":"10.1001\/archneur.1988.00520290115023"},{"issue":"1","key":"551_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-68908-0","volume":"10","author":"A Cutruzzol\u00e0","year":"2020","unstructured":"Cutruzzol\u00e0 A, Irace C, Frazzetto M, Sabatino J, Gullace R, De Rosa S, et al. Functional and morphological cardiovascular alterations associated with neurofibromatosis 1. Sci Rep. 2020;10(1):1\u20139.","journal-title":"Sci Rep"},{"issue":"5","key":"551_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.echo.2010.03.019","volume":"23","author":"L Lopez","year":"2010","unstructured":"Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 2010;23(5):465\u201395.","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"551_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.echo.2015.11.016","volume":"29","author":"PT Levy","year":"2016","unstructured":"Levy PT, Machefsky A, Sanchez AA, Patel MD, Rogal S, Fowler S, et al. Reference ranges of left ventricular strain measures by two-dimensional speckle-tracking echocardiography in children: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2016;29(3):209-25.e6.","journal-title":"J Am Soc Echocardiogr"},{"key":"551_CR26","unstructured":"General Authorisation to Process Personal Data for Scientific Research Purposes. Deliberated March 1, 2012. Gazzetta Ufficiale della Repubblica Italiana. n. 72. 2012."},{"issue":"8","key":"551_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","volume":"14","author":"C Robert","year":"2013","unstructured":"Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol. 2013;14(8):733\u201340.","journal-title":"Lancet Oncol"},{"issue":"24","key":"551_CR28","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1161\/CIRCULATIONAHA.107.754424","volume":"118","author":"G Buckberg","year":"2008","unstructured":"Buckberg G, Hoffman JIE, Mahajan A, Saleh S, Coghlan C. Cardiac mechanics revisited: the relationship of cardiac architecture to ventricular function. Circulation. 2008;118(24):2571\u201387.","journal-title":"Circulation"},{"issue":"9","key":"551_CR29","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911\u201339.","journal-title":"J Am Soc Echocardiogr"},{"issue":"13","key":"551_CR30","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900\u20139.","journal-title":"Eur J Cancer"},{"issue":"3","key":"551_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"551_CR32","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910\u20136.","journal-title":"J Clin Oncol"},{"issue":"13","key":"551_CR33","doi-asserted-by":"publisher","first-page":"E1248","DOI":"10.1016\/S0735-1097(12)61248-0","volume":"59","author":"T Negishi","year":"2012","unstructured":"Negishi T, Negishi K, Agler D, Plana J, Haluska B, Marwick T. Cardio-protective effect of beta-blockade during chemotherapy for breast cancer. J Am Coll Cardiol. 2012;59(13):E1248.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"551_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","volume":"26","author":"K Negishi","year":"2013","unstructured":"Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493\u20138.","journal-title":"J Am Soc Echocardiogr"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00551-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T19:04:13Z","timestamp":1676487853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00551-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,18]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00551-w","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,18]]},"assertion":[{"value":"30 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas Caiffa, Antimo Tessitore, Andrea Magnolato, Matilde Petz, Marco Bobbo, Daniela Chicco, Biancamaria D\u2019Agata Mottolese, Aldostefano Porcari, Egidio Barbi, Gianfranco Sinagra and Irene Bruno have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethics committee approval was not requested according to the Italian Law (Authorization no. 9\/2014).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"We received informed consent from the patients\u2019 parents and the patients themselves.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"We received informed consent from the patients\u2019 parents and the patients themselves.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All relevant data are included in the article and\/or its supplementary information files. All other data supporting the study (such as radiological photos or images) are available from the corresponding author upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AT and TC wrote the first draft of the manuscript. TC, MB, DC and BDAM collected and processed the data. MP reviewed the literature. EB, AM, IB, AP and GS critically revised the manuscript for relevant intellectual content. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}